PRIME-XV T Cell CDM is the first commercially available chemically defined, animal component-free medium for the expansion and cultivation of human T cells. The performance and functionality of PRIME-XV T Cell CDM continues to set the standard as the application process becomes more dynamic and closed.

Provides optimal performance:

• Supports vigorous T cell growth in static and dynamic automation systems while maintaining functionality
• Provides lot-to-lot consistency for reliable formulation composition
• Removes the effects of undefined components to minimize unwarranted T cell phenotypes
• Supports polarization to targeted T cell types such as Th₁ and T regulatory cells to further possible therapy applications

Manufactured to facilitate transfer from research to clinic:

• Chemically defined, animal component-free formula minimizes risks from adventitious agents
• Manufactured in compliance with cGMP regulations
• Traceability documentation provided including Certificates of Analysis, Certificates of Origin, and a Drug Master File (DMF) filed with the US FDA
• Extensive QC testing including functionality, sterility, and endotoxin
• Mycoplasma USP <63> testing is standard on all lots
• Custom formulation, sizes and packaging available for all commercially available automation systems

Figure 1: (A) Fold expansion of CD3+ cells in PRIME-XV T Cell CDM is robust across the three documented culture systems, performing as well as or better than FBS-supplemented RPMI and commercially available XSF media. (B) Viability is maintained at or above 85% by the end of the culture period in all three cell culture systems. Though significant inter-donor variability is observed, these data are representative of three donors, analyzed on day 14 (plates, flasks and G-Rex) or day 9 (Quantum bioreactors).

Publication, presentation, and protocol available for download

• Protocols support G-Rex and Quantum
• Protocols for plates and flasks can be provided